Substantial revenue from its flagship drug Casgevy should be right around the corner. Investors can

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) to

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% chan

Crisper Therapeutics (CSPR), Arista Networks (ANET), and Nebius (NBIS) are all seeing outsized intra

Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect

The recommendations of Wall Street analysts are often relied on by investors when deciding whether t

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), t

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it

CRISPR Therapeutics has two important data readouts coming up soon. In both cases, it'll need to dem

Septerna (NASDAQ: SEPN - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) a

CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) General Counsel James Kasinger sold 10,400 s

CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and managem

CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editin

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below wh

Even if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show

CRISPR Therapeutics will likely be a much larger company in 10 years. Much of that time will be spen

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or H

CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Theref

CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company's commercial and clinical pri

Cathie Wood explains why Tesla, Coinbase, and CRISPR lead her "Rapid Real Growth" thesis as

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the fu

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial e

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on posi

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the anal

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) w

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the te

Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Per

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challengin

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday.

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biote